KOREA WHO

Kim Sun-jin is the President and CEO of Kolon Life Science. He also serves as CEO of the new drug development division at Kolon Pharmaceutical and as Chief Medical Officer (CMO) of Kolon TissueGene.

He was born on September 15, 1961.

He graduated from Seoul National University College of Medicine, where he also earned a master’s degree in medicine and a Ph.D. in immunology.

He began his medical career as a urology fellow at Seoul National University Hospital, then served as an assistant professor in the Department of Urology at Hanyang University College of Medicine, and later as a professor at the University of Texas MD Anderson Cancer Center in the United States. He entered the pharmaceutical industry as Executive Vice President and Head of R&D at Hanmi Pharmaceutical.

He founded FlatBio, a biotechnology company specializing in new drug development. His relationship with Kolon began when he served as an outside director at Kolon TissueGene, after which he joined the company as Chief Medical Officer (CMO).

In 2023, he was appointed CEO of Kolon Life Science and subsequently became CEO of the new drug development division at Kolon Pharmaceutical following its merger with FlatBio.

He played a key role in overcoming the Invossa crisis and resuming Phase 3 clinical trials of Invossa in the United States.

#KolonLifeScience #KimSunjin #biopharma #Invossa #KolonTissueGene #newdrugdevelopment #biotechnology #R&D #HanmiPharmaceutical #FlatBio